Blueprint Medicines (BPMC) announced Sunday that its Phase 1 trial of avapritinib showed strong clinical activity.
Blueprint Medicines gapped open sharply higher Monday, but was range-bound throughout the session. Shares finished up by 16.46 at $88.32 with volume at over a 5-month high. The stock broke out of over a 2-month trading range and set a new high for the year.
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com